Beyond Gene Dosage: Understanding Down Syndrome via 4D Genome Organization
Beyond Gene Dosage: Understanding Down Syndrome via 4D Genome Organization
批准号:
10264939
负责人:
Wenbo Li
金额:
$62.42万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-18 至 2025-08-31
关键词:
3-DimensionalATAC-seqAffectAlzheimer&aposs DiseaseAminesAmyloidAneuploidyArchitectureAreaAstrocytesBiological AssayBrainBromodomainCRISPR interferenceCell Differentiation processCell NucleusCellsChIP-seqChemicalsChromatinChromosome 21Chromosome abnormalityChromosomesCongenital Heart DefectsDNADataDevelopmentDiseaseDisease modelDown SyndromeEnhancersEpigenetic ProcessEtiologyGene DosageGene ExpressionGene Expression RegulationGenesGeneticGenetic DiseasesGenetic TranscriptionGenomeGoalsHematopoieticHi-CHistonesHomo sapiensHumanHuman ChromosomesHuman DevelopmentHuman GeneticsImpaired cognitionIn SituIndividualInfantInterphase ChromosomeKnowledgeLeftLightMalignant NeoplasmsMediatingMethodsMicrogliaModelingMolecularMuscle hypotoniaNeurodevelopmental DisorderNeurogliaNeuronsNuclear Pore ComplexOncogene DeregulationOrganoidsPathologicPatientsPhasePlayPresenile Alzheimer DementiaProteinsRNAReaderRegulationResearch PersonnelRoleTechniquesTechnologyTestingTherapeuticTrisomyUntranslated RNAWorkbasebrain cellcell typecongenital heart disorderdevelopmental diseasedisease phenotypeepigenetic drugepigenomeexperimental studygenome-widehistone modificationhuman diseaseinduced pluripotent stem cellinhibitor/antagonistinsightnanoporenerve stem cellnovelnovel therapeutic interventionoptogeneticsprogramssuccesstooltranscriptome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Chromosomal aneuploidy underlies a variety of human diseases. The most prominent paradigm among these
is Down syndrome (DS) that is caused by an extra copy of homo sapiens chromosome 21 (HSA21). As the
most common genetic disease of human cognitive impairment, DS affects about 1 in 750 live-born infants in
the US, and it pre-disposes patients to muscle hypotonia, dysmorphic features, congenital heart defects and
early onset Alzheimer's disease. Despite many progress, our conceptual understanding of the pathological
basis of such chromosomal abnormality is so far largely limited to the “gene dosage hypothesis”, which
however cannot explain broad gene deregulation that takes place throughout the genome in specific cell types.
It has been unexplored that whether 3D genome mal-folding may play yet unrealized roles in DS and other
aneuploidies. Here, we assembled a strong team to test an overall hypothesis that the presence of trisomy 21
deregulates 3D genome as an entirety and changes gene expression in DS cells, particularly via forming
aberrant inter-chromosomal interactions (ICIs). We have two specific aims. In Aim-1, in multiple pairs of
isogenic iPSC cells and their derived neuron/glia cells that contain disomic versus trisomy HSA21, we will
conduct assays to systematically characterize their 3D genome (in situ Hi-C and PLAC-Seq), transcriptome
and 1D epigenome (PRO-Seq, ATAC-Seq, and histone modification ChIP-Seq). Integrative analyses will
dissect the aberrant chromatin interactomes, particularly these interchromosomal interactions altered in trisomy
nucleus, and correlate those with gene deregulation in specific developmental stages or cell types (neurons,
astrocytes or microglia). We will use leading-edge new techniques based on long reads sequencing to further
characterize aberrant inter-chromosomal interactions, and will validate them using DNA and/or RNA FISH. In
Aim-2, we focus on functionally dissecting the roles of aberrant inter-chromosomal interactions in gene
deregulation. This will be first investigated by chemical and epigenetic perturbation in both cultured primary
neural progenitor cells and in brain cortical organoids. We will then use novel optogenetic tools to model
disease-relevant formation of ICIs to deduce their potential causal roles in gene deregulation. The expected
results from this proposal are significant not only to our understanding of the 4D genome, but also to human
brain developmental disorders. The knowledge generated here will shed light on many forms of aneuploidy,
providing a new conceptual framework beyond “gene dosage effects” to understand gene deregulation, and
inspire strategies to ameliorate these diseases via restoring 3D genome architecture.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancer RNAs in brain gene regulation and Alzheimer's disease
-
批准号:10667052
-
项目类别:
-
资助金额:$78.38万
-
财政年份:2023
-
负责人:Wenbo Li
-
依托单位:
Beyond Gene Dosage: Understanding Down Syndrome via 4D Genome Organization
-
批准号:10689799
-
项目类别:
-
资助金额:$62.42万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Mechanisms Underlying Enhancer Rnp Mediated Gene Regulation And Genome Organization
-
批准号:10260610
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Mechanisms Underlying Enhancer Rnp Mediated Gene Regulation And Genome Organization
-
批准号:10687073
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Beyond Gene Dosage: Understanding Down Syndrome via 4D Genome Organization
-
批准号:10487485
-
项目类别:
-
资助金额:$62.42万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Mechanisms Underlying Enhancer Rnp Mediated Gene Regulation And Genome Organization
-
批准号:10461048
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Mechanisms Underlying Enhancer Rnp Mediated Gene Regulation And Genome Organization
-
批准号:10389423
-
项目类别:
-
资助金额:$19.49万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Beyond Gene Dosage: Understanding Down Syndrome via 4D Genome Organization
-
批准号:10117780
-
项目类别:
-
资助金额:$63.83万
-
财政年份:2020
-
负责人:Wenbo Li
-
依托单位:
Optogenetic Engineering of 3D Chromatin Architecture
-
批准号:10004126
-
项目类别:
-
资助金额:$23.06万
-
财政年份:2019
-
负责人:Wenbo Li
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: